Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More
Exalpha Biologicals, Inc.

Cycloscope B-All

  • Product Code: 7043
  • Size: 20 Tests
  • Availability: In Stock In Stock
  • Price (USD): $682

Cat #

7043		 Quantity:      

Data Sheet

Product Name

Cycloscope B-All

Product Type

Flow Cytometry Kits

Applications

Flow Cytometry

Size

20 Tests

Price (USD)

$682

Background

Cycloscope B-ALL, is a kit used for the flow cytometric analysis of DNA cell contents in B-lineage acute lymphoblastic leukemia (B-ALL). This kit is mainly focused for DNA studies of leukemic blast cells from bone marrow samples of these patients. Introduction: Acute lymphoblastic leukemia is a disorder characterized by a clonal expansion of lymphoid progenitor cells arrested at different differentation steps whose progressive accumulation causes bone marrow involvement with more than 30% blast cells at diagnosis. According to the European Group for the Immunological Clasification of Leukemias, assignement of an ALL to the B-lineage is based on the expression on leukemic cells of at least two B lineage associated antigens: CD19, cytoplasmic CD79a (mb-1) or cytoplasmic CD22. DNA cell content studies by flow cytometry provide relevant information for the prognostic evaluation and follow-up of patients with acute lymphoblastic leukemia. Detection of hyperdiploid leukemic blast cells is an independent prognostic factor strongly associated with favourable clinical and biologic features (1-3); in addition it may be of great utility for the detection of minimal residual disease contributing to relapse prediction in these patients (4, 5). At present the clinical utility of cell cycle studies in B-lineage ALL still remains to be established (6).

Customer Storage

Product should be stored at 4-8°C. DO NOT FREEZE

References

1. Trueworthy R, Shuster J, Look AT, Crist WM, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V. Ploidy of lymphoblast is the stronger predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a pediatric oncology group study. J Clin Oncol 10: 606-613; 1992.

2. Pui CH, Raimondi SC, Dodge R, Rivera GK, Fuchs LAH, Abromowitch M, Look AT, Furman WL, Crist WM, Williams D. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (>50 chromosomes) acute lymphoblastic leukemia. Blood, 73: 1963-67; 1989.

3. Pui CH, Dodge RK, Look AT, George SL, Rivera GK, Abromowitch M, Ochs J, Evans WE, Crist WM, Simone JV. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude total therapy studies VIII, IX and X. Clin. Oncol. 9: 1341; 1991.

4. Nowak R, Oelschl